The facility is designed to serve customers with science-based, derma-driven wellness products
Iberia Pharmaceuticals announced its new hi-tech manufacturing and research facility spread across 60000 sq ft in Jhajjar, Haryana. The next-generation unit is expected to be operational by mid-2026. The facility is designed to serve customers with science-based, derma-driven wellness products. The company has invested Rs 70 crores.
The plant will focus on delivering economically viable solutions in a robust, compliant, and environmentally sustainable manner. The idea is to support customers who are seeking highly effective and personalised skin-care products.
The new facility is complementary to Iberia’s current discovery capabilities and infrastructure, including clinical-grade treatments, which primarily focus on nanotechnology-driven skincare solutions and therapeutic solutions with a strong pharmaceutical backbone. The products are vegan and built for high-performance skincare across diverse categories.
Nitin Jain, Founder, Iberia Pharmaceuticals said, “The opening of this facility is one of multiple strategic initiatives that Iberia is implementing to support rapid growth. It also shows our firm commitment to the continued expansion of our business, building on years of proven experience and will enable us to serve our global customers efficiently.”
At full scale, this manufacturing unit will make more than 12 million units a year in the areas of dermatology, wellness and chronic care for the Indian and global markets. The company will also generate 600+ jobs in this facility.
“Iberia believes in delving deep into research of science-backed skincare, leverages cutting-edge nanotechnology to bring products that are pushing the boundaries of innovation and setting new benchmarks in dermatological excellence, expanding steadily into wellness and chronic care,” said Saurav Ojha, Co-Founder, Iberia Pharmaceuticals.
